The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders inflammatory diseases cardiovascular diseases nephropathies glaucoma spasticity cancer osteoporosis metabolic disorders obesity addiction dependence abuse and relapse related disorders psychiatric and neurological disorders neurodegenerative disorders autoimmune hepatitis and encephalitis pain reproductive disorders and skin inflammatory and fibrotic diseases.
